Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy

Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy

Background Cardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life. In this review, we evaluated the pharmacologic profile and clinical outcomes for mavacamten and aficamten, 2 cardiac myos...

Full description

Saved in:

Bibliographic Details
Main Authors:	Bryton J. Davis, Hailey Volk, Olives Nguyen, Daniel Kamna, Hongya Chen, Roberto Barriales‐Villa, Pablo Garcia‐Pavia, Iacopo Olivotto, Anjali T. Owens, Caroline J. Coats, Theodore P. Abraham, Scott D. Solomon, Martin S. Maron, Ahmad Masri
Format:	Article
Language:	English
Published:	Wiley 2025-03-01
Series:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:	aficamten cardiac myosin inhibitors mavacamten symptomatic hypertrophic cardiomyopathy
Online Access:	https://www.ahajournals.org/doi/10.1161/JAHA.124.038758
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comprehensive Review: Mavacamten and Aficamten in Hypertrophic Cardiomyopathy
by: Helin Savsin, et al.
Published: (2025-07-01)

Obstructive hypertrophic cardiomyopathy: from genetic insights to a multimodal therapeutic approach with mavacamten, aficamten, and beyond
by: Khadija Sarwer, et al.
Published: (2024-12-01)

Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM
by: Caroline J. Coats, et al.
Published: (2024-08-01)

Cardiac myosin inhibitors: Efficacy, safety and future directions of aficamten in hypertrophic obstructive cardiomyopathy
by: Ikponmwosa Jude Ogieuhi, et al.
Published: (2025-06-01)

The effect of mavacamten on echocardiographic parameters, cardiac function and biomarkers in hypertrophic cardiomyopathy patients, a systematic review and meta-analysis
by: Zina Otmani, et al.
Published: (2025-07-01)

British Society of Echocardiography guideline for the transthoracic echocardiographic assessment of adult patients with obstructive hypertrophic cardiomyopathy receiving myosin-inhibitor therapy
by: Clare M. Culshaw, et al.
Published: (2025-06-01)

Hypertrophic Cardiomyopathy with Special Focus on Mavacamten and Its Future in Cardiology
by: Ewelina Młynarska, et al.
Published: (2024-11-01)

Temporal Patterns of Holter-Detected Arrhythmias in Hypertrophic Cardiomyopathy Patients Treated with Mavacamten
by: Amro Badr, et al.
Published: (2025-04-01)

Effect of Mavacamten on Echocardiographic Features in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Results from the EXPLORER-CN Study
by: Zhuang Tian, et al.
Published: (2025-04-01)

Mavacamten in real‐life practice: Initial experience at a hypertrophic cardiomyopathy centre
by: Zaid Abood, et al.
Published: (2025-02-01)

Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response
by: Anjali T. Owens, et al.
Published: (2024-09-01)

Recent Advances in Novel Modulators for Cardiac Myosin Disorders
by: Hancheng Wang, et al.

Editorial: State-of-the-art muscle physiology research: from single molecules and cells to living organisms
by: Norio Fukuda, et al.
Published: (2025-06-01)

Eighteen‐Month Real‐World Experience Using Mavacamten for Treatment of Obstructive Hypertrophic Cardiomyopathy in a Racially Diverse Population
by: Diego Ramonfaur, et al.
Published: (2024-08-01)

An ALPK3 truncation variant causing autosomal dominant hypertrophic cardiomyopathy is partially rescued by mavacamten
by: Lisa Leinhos, et al.
Published: (2025-03-01)

Integrative Approaches in the Management of Hypertrophic Cardiomyopathy: A Comprehensive Review of Current Therapeutic Modalities
by: Marco Maria Dicorato, et al.
Published: (2025-05-01)

Mavacamten
by: Matthew W. Martinez, MD, et al.
Published: (2025-01-01)

Atrial remodelling and dysfunction in hypertrophic cardiomyopathy: prognostic role and therapeutic target
by: Chiara Piazzai, et al.
Published: (2025-07-01)

Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials
by: Ayesha Aman, et al.
Published: (2025-02-01)

Diagnostic Challenges and Management of Hypertrophic Cardiomyopathy with Left Ventricular Outflow Tract Obstruction in a Patient with Hypertension
by: Nina Marta Kubikowska, et al.
Published: (2025-04-01)

Myosin Modulators Mavacamten and Aficamten Inhibit Cardiac Contractility Through Different Mechanisms
by: Saffie Mohran, et al.
Published: (2025-06-01)

Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis With High Surgical Risk
by: Omar M. Abdelfattah, MD, et al.
Published: (2025-07-01)

Hypertrophic cardiomyopathy occurred after successful surgical correction of supravalvular aortic stenosis: a case report of Williams–Beuren syndrome
by: Hongxiao Yu, et al.
Published: (2025-08-01)

Advancements in the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Comprehensive Review
by: Randeep Gill, et al.
Published: (2024-09-01)

Cryo-EM structures of cardiac muscle α-actin mutants M305L and A331P give insights into the structural mechanisms of hypertrophic cardiomyopathy
by: Hsiang-Ling Huang, et al.
Published: (2024-12-01)

Myosin relaxation states in skeletal muscle fibers of rats and mice: Effects of sex and adiposity
by: Zachery A. Roloff, et al.
Published: (2025-04-01)

Structure of the Inhibited Smooth Muscle Myosin and Its Implications on the Regulation of Insect Striated Muscle Myosin
by: Shaopeng Sun, et al.
Published: (2025-02-01)

A novel mutation of the MYH7 gene in a patient with hypertrophic cardiomyopathy
by: Nicholas Goel, et al.
Published: (2018-06-01)

Phenotype variation of hypertrophic cardiomyopathy in carriers of the p.Arg870His pathogenic variant in the MYH7 gene
by: A. N. Kucher, et al.
Published: (2022-10-01)

<i>MYBPC3</i> D389V Variant Induces Hypercontractility in Cardiac Organoids
by: Darshini Desai, et al.
Published: (2024-11-01)

Mavacamten maintenance dose determination: insights into individualised therapy for hypertrophic cardiomyopathy
by: Kawa Mohemed, et al.
Published: (2025-03-01)

Single Cell Transcriptomic Profiling of MYBPC3‐Associated Hypertrophic Cardiomyopathy Across Species Reveals Conservation of Biological Process But Not Gene Expression
by: Samia A. Ali, et al.
Published: (2025-01-01)

The Interaction of pT73-Rab10 with Myosin Va, but Not Myosin Vb, Is Regulated Though a Site in the Globular Tail Domain
by: Lynne A. Lapierre, et al.
Published: (2025-07-01)

Considering the effect of Pi rebinding on myosin dynamics based on the distinct functions of cardiac and skeletal myosin
by: Motoshi Kaya
Published: (2025-05-01)

Sustaining neuromuscular activation after total knee arthroplasty preserves skeletal muscle fiber size, contractility, and innervation in older adults
by: Michael J. Toth, et al.
Published: (2025-10-01)

Increased cardiac myosin super-relaxation as an energy saving mechanism in hibernating grizzly bears
by: Robbert J. Van der Pijl, et al.
Published: (2025-02-01)

Long‐Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER‐OLE Study
by: Ahmad Masri, et al.
Published: (2024-04-01)

Diagnostic Assessment of Status Epilepticus
by: J Gordon Millichap
Published: (2006-12-01)

Tropomodulin–Tropomyosin Interplay Modulates Interaction Between Cardiac Myosin and Thin Filaments
by: Galina V. Kopylova, et al.
Published: (2025-05-01)

Impacts of structural properties of myosin II filaments on force generation
by: Shihang Ding, et al.
Published: (2025-08-01)